Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — September 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #711

    Det er vel ikke et problem for ofa. Men det der kan være problemet er jo om det betyder noget. Naturligvis er effekt jo en meget vigtig parameter. Men hvis pts nu kan leve med RRMS i meget lang tid vil bivirkningerne være vigtige. Vi må se data 🙂

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #712

      https://www.ocrelizumabinfo.global/content/dam/ocrelizumab/global/en/documents/P4_2_025_AAN_2019_SafetyUpdatePoster_Global_Hauser_et_al_Supplemental_Mats_V2.pdf Analyse af sideeffects ved ocrelizumab.

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #713

        Så har vi benchmark her.

        1 Reply Last reply
        0
        • Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktørH Offline
          Helge_LarsenPI-redaktør
          wrote on sidst redigeret af
          #714

          Tak Solsen. 🙂

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #715

            God morgen. 🙂

            1 Reply Last reply
            0
            • T Offline
              T Offline
              transalp
              wrote on sidst redigeret af
              #716

              Go morgen.. 🙂

              1 Reply Last reply
              0
              • B Offline
                B Offline
                bibob
                wrote on sidst redigeret af
                #717

                God morgen fra syden. 🙂

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #718

                  Ser ikke ud til det store rebound idag.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #719

                    not sure if this new trial was posted already : Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma https://clinicaltrials.gov/ct2/show/NCT04052997?term=Camidanlumab&rank=1

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #720

                      Just a moment...

                      favicon

                      (www.firstwordpharma.com)

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #721

                        ADC Therapeutics IPO:

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #722

                          yes, that made me revisit this. here is the SEC form F1 https://sec.report/Document/0001140361-19-016305/

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #723

                            it contains a short explanation of ADCT-301 and also : Key elements of our strategy are outlined below:

                            • .
                            • Advance our second lead product candidate, ADCT-301, to support BLA submission in the first half of 2022.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #724

                              and then i also thought "Risks Related to Our Relationship with Third Parties" was interesting as it says "Our rights to ADCT-301 are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize ADCT-301."

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #725

                                Our collaboration and license agreement with Genmab requires a divestment of ADCT-301, in which Genmab has a 25% interest, following database lock for the Phase 1/2 clinical trial. The agreement sets out a defined process to facilitate the divestment of ADCT-301 by licensing the rights thereto to a third party, subject to Genmab’s right of first opportunity to negotiate to acquire ADCT-301 in full.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #726

                                  p148 is also interesting

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #727

                                    the Lundbeck Parkinson's trial a bit delayed, doesn't seem to recruit very enthusiastically https://clinicaltrials.gov/ct2/history/NCT03611569?A=2&B=3&C=merged#StudyPageTop

                                    1 Reply Last reply
                                    0
                                    • StockBullS Offline
                                      StockBullS Offline
                                      StockBull
                                      wrote on sidst redigeret af
                                      #728

                                      Kursen søger ned mod styrkeområdet 1360-80. Tror der ligger den del s.l i det område.Vi må håbe de 1360 holder.

                                      1 Reply Last reply
                                      0
                                      • A Offline
                                        A Offline
                                        AaBforever
                                        wrote on sidst redigeret af
                                        #729

                                        Lad os få good news så den kan søge opad igen..:-)

                                        1 Reply Last reply
                                        0
                                        • K Offline
                                          K Offline
                                          kkjoel
                                          wrote on sidst redigeret af
                                          #730

                                          Ja, yderst interessant EL. Har GEN virkelig stadig muligheden fo
                                          r at "genovertage" ADCT-301.....??

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger